Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.50 |
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28922699 | 0.98 | HSD11B1 (0.50) | HSD11B1TRPA1ARAKR1C3AKR1C2 | |
| SCHEMBL22304414 | 0.89 | AR (0.58) | HSD11B1TRPA1ARFFAR4BACE1 | |
| SCHEMBL24297565 | 0.87 | AR (0.56) | HSD11B1TRPA1ARFFAR4BACE1 | |
| SCHEMBL11286015 | 0.83 | KIF11 (0.54) | HSD11B1TRPA1ARFFAR4BACE1 | |
| SCHEMBL29980535 | 0.83 | KIF11 (0.54) | HSD11B1TRPA1ARFFAR4BACE1 | |
| SCHEMBL5523215 | 0.83 | KIF11 (0.54) | HSD11B1TRPA1ARFFAR4BACE1 | |
| SCHEMBL14296195 | 0.82 | AKR1C3 (0.40) | HSD11B1TRPA1ARAKR1C3AKR1C2 | |
| SCHEMBL163729 | 0.82 | HSD11B1 (0.55) | HSD11B1TRPA1ARFFAR4BACE1 | |
| SCHEMBL30679727 | 0.81 | NR3C1 (0.52) | HSD11B1TRPA1ARFFAR4BACE1 | |
| Benzene SCHEMBL29143034 | 0.80 | AR (0.50) | HSD11B1TRPA1ARFFAR4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| WO-2023156485-A1 | TRIARYLALKYL BORATE SALTS AS COINITIATORS IN NIR PHOTOPOLYMER COMPOSITIONS | COVESTRO DEUTSCHLAND AG (DE) | 2023-08-24 | — | — | WO | disclosed |
| EP-3242875-B1 | 4,5-DIHYDROIMIDAZOLE DERIVATIVES AND THEIR USE AS HISTONE DEMETHYLASE (KDM2B) INHIBITORS | GENENTECH INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3885343-A1 | INDOLE COMPOUNDS AS EZH2 INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2016112251-A1 | 4,5-DIHYDROIMIDAZOLE DERIVATIVES AND THEIR USE AS HISTONE DEMETHYLASE (KDM2B) INHIBITORS | GENENTECH, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-7256206-B2 | 1-[4-(3-Amino-4-hydroxy-3-hydroxymethyl-butyl)-phenyl]-ethanone-O-biphenyl-4-ylmethyl-oxime, used as modulators of lipid activated G-protein coupled receptors specific for sphingosine-1-phosphate; prevention of autoimmune diseases or as angiogenesis inhibitors | IRM LLC (BM) | 2007-08-14 | — | — | US | disclosed |
| US-7256206-B2 | 1-[4-(3-Amino-4-hydroxy-3-hydroxymethyl-butyl)-phenyl]-ethanone-O-biphenyl-4-ylmethyl-oxime, used as modulators of lipid activated G-protein coupled receptors specific for sphingosine-1-phosphate; prevention of autoimmune diseases or as angiogenesis inhibitors | IRM LLC (BM) | 2007-08-14 | — | — | US | disclosed |
| CN-1802350-A | Azetidinecarboxamide derivatives and their use in the treatment of CB1Use in receptor-mediated disorders | VERNALIS RES LTD (GB) | 2006-07-12 | — | — | CN | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0513974-B1 | Novel benzo-fused lactams that promote the release of growth hormone | MERCK & CO INC (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5310737-A | Benzo-fused lactams that promote the release of growth hormone | MERCK & CO., INC. (US) | 1994-05-10 | — | — | US | disclosed |
| US-5206235-A | Animal growth regulators; stimulants | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0513974-A1 | Novel benzo-fused lactams that promote the release of growth hormone | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| WO-1992016524-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | BCL6, BCL6B, EZH2 | HSD11B1 3544/4885TRPA1 4872/4885AR 1743/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HSD11B1 256/4885TRPA1 3038/4885AR 254/4885 |
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | OCIAD1, OCIAD2, SLCO4C1 | HSD11B1 608/4885TRPA1 280/4885AR 1888/4885 |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | HSD11B1 637/4885TRPA1 4682/4885AR 525/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | HSD11B1 977/4885TRPA1 4884/4885AR 2265/4885 |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BAZ2A | HSD11B1 837/4885TRPA1 4635/4885AR 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.